UK Regulator Endorses Alzheimer's Drug Kisunla
This is a UK news story, published by ABC News, that relates primarily to the National Health Service news.
UK news
For more UK news, you can click here:
more UK newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsABC News news
For more news from ABC News, you can click here:
more news from ABC NewsAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
competitor drug Leqembi. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest drug Kisunla news, new treatment options news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
drug regulatorABC News
•UK regulator approves second Alzheimer's drug in months but government won't pay for it
88% Informative
UK regulator approves second Alzheimer's drug in months but government won't pay for it.
Independent watchdog agency said the treatment isn't worth the cost to taxpayers.
Kisunla, also known as donanemab, works by removing a sticky protein from the brain believed to cause Alzheimer’s disease.
In August , the U.K. regulator authorized the drug while the same watchdog agency issued draft guidance recommending against its purchase for the National Health Service .
VR Score
92
Informative language
93
Neutral language
57
Article tone
formal
Language
English
Language complexity
67
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
4
Source diversity
3
Affiliate links
no affiliate links